Literature DB >> 19356817

Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer.

Valérie Fonteyne1, Geert Villeirs, Nicolaas Lumen, Gert De Meerleer.   

Abstract

BACKGROUND AND
PURPOSE: Urinary toxicity plays a major role in the quality of life (QOL) of patients treated with external beam radiotherapy as primary therapy for prostate cancer. In this study we report on: (1) Incidence of acute and late GU toxicity after intensity modulated radiotherapy (IMRT) for prostate cancer at Ghent University Hospital (GUH). (2) Time evolution of pre-IMRT and IMRT-induced acute and late GU toxicity.
MATERIALS AND METHODS: At GUH, 260 patients with a follow-up of > or = 12 months were treated with IMRT for prostate cancer. The incidence and evolution of GU toxicity were recorded.
RESULTS: Acute grades 3, 2 and 1 GU toxicity occurred in 8%, 42% and 42% of the patients, respectively. Late grades 3, 2 and 1 GU toxicity occurred in 3%, 19% and 40% of the patients, respectively. During therapy baseline grade 1 symptoms increased into grade 2 acute GU toxicity in 48%. After 1 and 2 years, 60% and 70% of the patients, respectively, had less GU symptoms when compared to the pre-treatment status.
CONCLUSION: IMRT induces mild GU toxicity. There is an improvement in pre-IMRT obstructive miction disorders.

Entities:  

Mesh:

Year:  2009        PMID: 19356817     DOI: 10.1016/j.radonc.2009.03.013

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  14 in total

1.  Multisource Rotating Shield Brachytherapy Apparatus for Prostate Cancer.

Authors:  Hossein Dadkhah; Karolyn M Hopfensperger; Yusung Kim; Xiaodong Wu; Ryan T Flynn
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-06-20       Impact factor: 7.038

2.  High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer.

Authors:  Pirus Ghadjar; Nicole Gwerder; Peter Manser; Jacqueline Vock; Axel Madlung; Roberto Mini; Daniel M Aebersold
Journal:  Strahlenther Onkol       Date:  2010-11-30       Impact factor: 3.621

3.  Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer: implications for defining postradiotherapy urinary toxicity.

Authors:  Pirus Ghadjar; Andrew Jackson; Daniel E Spratt; Jung Hun Oh; Per Munck af Rosenschöld; Marisa Kollmeier; Ellen Yorke; Margie Hunt; Joseph O Deasy; Michael J Zelefsky
Journal:  Eur Urol       Date:  2013-02-14       Impact factor: 20.096

4.  Early clinical experience of radiotherapy of prostate cancer with volumetric modulated arc therapy.

Authors:  Gianfranco A Pesce; Alessandro Clivio; Luca Cozzi; Giorgia Nicolini; Antonella Richetti; Emanuela Salati; Mariacarla Valli; Eugenio Vanetti; Antonella Fogliata
Journal:  Radiat Oncol       Date:  2010-06-16       Impact factor: 3.481

5.  Impact of bladder volume on acute genitourinary toxicity in intensity modulated radiotherapy for localized and locally advanced prostate cancer.

Authors:  Arne Grün; Michael Kawgan-Kagan; David Kaul; Harun Badakhshi; Carmen Stromberger; Volker Budach; Dirk Böhmer
Journal:  Strahlenther Onkol       Date:  2018-11-15       Impact factor: 3.621

6.  Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer.

Authors:  Valérie Fonteyne; Nicolaas Lumen; Geert Villeirs; Piet Ost; Gert De Meerleer
Journal:  Adv Urol       Date:  2011-11-30

7.  Dose escalation using ultra-high dose IMRT in intermediate risk prostate cancer without androgen deprivation therapy: preliminary results of toxicity and biochemical control.

Authors:  Maria Grazia Petrongari; Valeria Landoni; Biancamaria Saracino; Sara Gomellini; Stefano Arcangeli; Giuseppe Iaccarino; Paola Pinnarò; Giorgio Arcangeli; Lidia Strigari
Journal:  J Exp Clin Cancer Res       Date:  2013-12-13

8.  Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.

Authors:  Leonard N Chen; Simeng Suy; Sunghae Uhm; Eric K Oermann; Andrew W Ju; Viola Chen; Heather N Hanscom; Sarah Laing; Joy S Kim; Siyuan Lei; Gerald P Batipps; Keith Kowalczyk; Gaurav Bandi; John Pahira; Kevin G McGeagh; Brian T Collins; Pranay Krishnan; Nancy A Dawson; Kathryn L Taylor; Anatoly Dritschilo; John H Lynch; Sean P Collins
Journal:  Radiat Oncol       Date:  2013-03-13       Impact factor: 3.481

9.  Toxicity and Long-Term Outcomes of Dose-Escalated Intensity Modulated Radiation Therapy to 74Gy for Localised Prostate Cancer in a Single Australian Centre.

Authors:  Joseph Sia; Daryl Lim Joon; Angela Viotto; Carmel Mantle; George Quong; Aldo Rolfo; Morikatsu Wada; Nigel Anderson; Maureen Rolfo; Vincent Khoo
Journal:  Cancers (Basel)       Date:  2011-09-01       Impact factor: 6.639

10.  Early results of urethral dose reduction and small safety margin in intensity-modulated radiation therapy (IMRT) for localized prostate cancer using a real-time tumor-tracking radiotherapy (RTRT) system.

Authors:  Shinichi Shimizu; Kentaro Nishioka; Ryusuke Suzuki; Nobuo Shinohara; Satoru Maruyama; Takashige Abe; Rumiko Kinoshita; Norio Katoh; Rikiya Onimaru; Hiroki Shirato
Journal:  Radiat Oncol       Date:  2014-05-21       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.